Prostate Biopsy Sampling Causes Hematogenous Dissemination of Epithelial Cellular Material-Reference-Cited by-同舟云学术

Prostate Biopsy Sampling Causes Hematogenous Dissemination of Epithelial Cellular Material

Published:2014 Issue: Volume:2014 Page:1-6
ISSN:0278-0240
Container-title:Disease Markers
language:en
Short-container-title:Disease Markers

Author:

Ladjevardi Sam¹,Auer Gert²,Castro Juan³,Ericsson Christer³,Zetterberg Anders³,Häggman Michael¹,Wiksell Hans⁴^ORCID,Jorulf Håkan⁵

Affiliation:

1. Surgical Science, Uppsala University, 751 85 Uppsala, Sweden

2. Karolinska Biomic Center, Karolinska Institutet, 171 76 Stockholm, Sweden

3. Department of Oncology-Pathology, CCK R8:04, Karolinska Institutet, 171 76 Stockholm, Sweden

4. Department of Molecular Medicine and Surgery, Karolinska Institutet, c/o Hans Wiksell, Comair AB, P.O. Box 39011, 100 54 Stockholm, Sweden

5. Radiology, Oncology and Radiation Science, Section of Radiology, Uppsala University, 751 85 Uppsala, Sweden

Abstract

The extent of epithelial cellular material (ECM) occurring in venous blood samples after diagnostic core needle biopsy (CNB) was studied in 23 patients with CNB diagnosed prostate cancer without provable metastases and 15 patients without cancer. The data show a significant increase of ECM in the peripheral blood sampled 20 seconds or 30 minutes after the last of 10 CNB procedures compared to the number of ECM detectable in the blood samples taken before the performance of CNB. The data indicate that diagnostic CNB of prostate cancer causes an extensive tissue trauma with a potential risk of cancer cell dissemination.

Funder

AFA Försäkring

Publisher

Hindawi Limited

Subject

Biochemistry, medical,Clinical Biochemistry,Genetics,Molecular Biology,General Medicine

Link

http://downloads.hindawi.com/journals/dm/2014/707529.pdf

Reference12 articles.

1. Cancer Statistics, 2009

2. Evidence to Support a Continued Stage Migration and Decrease in Prostate Cancer Specific Mortality

3. Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005